Home › IGA Glomerulonephritis › NCT07054684
Study of BHV-1400 in IgA Nephropathy
RecruitingPhase 1
An Open-Label Biomarker Study of BHV-1400 in IgA Nephropathy
Who can join
Ages 18 to 65 · All sexes
Full eligibility criteria
Key Inclusion Criteria: 1\. Participants must have biopsy-confirmed IgA Nephropathy Key Exclusion Criteria: 1. Any secondary IgAN 2. Any cause of chronic kidney disease not diagnosed as IgAN or due to non-IgAN cause
About the study
The purpose of this study is to determine if BHV-1400 is a safe and tolerable treatment in participants with IgA Nephropathy (IgAN).
What is being tested
- BHV-1400 (drug)
Sponsor: Biohaven Therapeutics Ltd. · Participants: 20 · Started: Jul 30, 2025
Contact the study team
- Chief Medical Officer · Phone: 203-404-0410
Official record on ClinicalTrials.gov — NCT07054684
Locations in the U.S.
| Connecticut | Site-001, Farmington |
| Florida | Site-003, Miami Lakes Site-011, Miami Lakes Site-013, Orlando Site-005, Pembroke Pines |
| Georgia | Site-008, Lawrenceville |
| Illinois | Site-009, Hinsdale |
| Indiana | Site-012, Indianapolis |
| Michigan | Site-015, Shelby |
| Missouri | Site-006, Chesterfield |
| South Dakota | Site-002, Dakota Dunes |
| Texas | Site-004, Houston Site-014, Houston |
| Utah | Site-016, Salt Lake City |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.